Bone Health

Clinical Publications

• Ligand-Independent Androgen Receptor Activity is Activation Function-2-Independent and Resistant to Antiandrogens in Androgen Refractory Prostate Cancer Cells
  Monday, 18 February 2008
• ASCO GU 2008 - High-Risk Disease after Radical Retropubic Prostatectomy : The Case for Systemic Treatment
  Saturday, 16 February 2008
• ASCO GU 2008 - Cardiovascular Mortality Following Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: Analysis of ROG 85-31
  Friday, 15 February 2008
• ASCO GU 2008 - Radiation Therapy: How Much Androgen Deprivation Therapy is Enough?
  Friday, 15 February 2008
• ASCO GU 2008 - Androgen Receptor Reactivation after Androgen Deprivation Therapy
  Friday, 15 February 2008
• Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610
  Monday, 21 January 2008
• Mechanisms of Androgen Receptor Activation in Advanced Prostate Cancer: Differential Co-Activator Recruitment and Gene Expression
  Wednesday, 16 January 2008
• Effects of Androgen Deprivation on Glycaemic Control and on Cardiovascular Biochemical Risk Factors in Men with Advanced Prostate Cancer with Diabetes
  Monday, 14 January 2008
• SUO 2007 - Prostate Cancer II: "HRQOL and Prostate Cancer Treatment":"Impact of Androgen Deprivation Therapy on the Health of Prostate Cancer"
  Monday, 03 December 2007
• Intraoperative Radiotherapy for Locally Advanced Prostate Cancer: Treatment Technique and Ultrasound-Based Analysis of Dose Distribution
  Monday, 03 December 2007
• Beyond the Abstract - Persistent Hypocalcemia Induced by Zoledronic Acid in a Patient with Androgen-Independent Prostate Cancer and Extensive Bone Metastases
  Friday, 23 November 2007
• Continuing Benefit of Zoledronic Acid in Preventing Skeletal Complications in Patients with Bone Metastases
  Thursday, 22 November 2007
• Combined Androgen Blockade in Advanced Prostate Cancer: Looking Back to Move Forward
  Wednesday, 21 November 2007
• Pathologic Effects of Testosterone Deprivation
  Friday, 09 November 2007
• Intermittent Versus Continuous Androgen Suppression for Prostatic Cancer
  Tuesday, 06 November 2007
• Bone Health in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy: The Role of Bisphosphonates – Abstract
  Friday, 26 October 2007
• Predictors of Skeletal Complications in Men with Hormone-Refractory Metastatic Prostate Cancer - Abstract
  Tuesday, 02 October 2007
• SIU 2007 MP [08.23] - Zoledronic Acid Produces Benefits in Patients with Early Malignant Bone Disease from Hormone-Refractory Prostate Cancer
  Tuesday, 04 September 2007
• SIU 2007 MP [08.12] - One Single Dose of Zoledronic Acid (Zometa) Annually Can Prevent Bone Mineral Density (BMD) in Patients with Prostate Cancer Treated with LHRH: Early Results of a Randomized Trial
  Tuesday, 04 September 2007
• The Effect of Zoledronic Acid on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy - Abstract
  Monday, 13 August 2007
• Lifestyle Factors and Duration of Androgen Deprivation Affect Bone Mineral Density of Patients with Prostate Cancer During First Year of Therapy - Abstracts
  Monday, 13 August 2007
• Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study - Abstract
  Friday, 10 August 2007
• Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist-Induced Bone Loss in Men with Prostate Cancer - Abstract
  Friday, 10 August 2007
• Zoledronic Acid Treatment at Home: Safety Data from an Observational Prospective Trial - Abstract
  Friday, 10 August 2007
• Decreases in Pain at Rest and Movement-Related Pain During Zoledronic Acid Treatment in Patients with Bone Metastases Due to Breast or Prostate Cancer: a Pilot Study - Abstract
  Thursday, 09 August 2007
• Suppression of Bone Density Loss and Bone Turnover in Patients with Hormone-Sensitive Prostate Cancer and Receiving Zoledronic Acid
  Tuesday, 07 August 2007
• Serial Markers of Bone Turnover in Men with Metastatic Prostate Cancer Treated with Zoledronic Acid for Detection of Bone Metastases Progression
  Friday, 04 May 2007
• The Risk of Renal Impairment in Hormone-Refractory Prostate Cancer Patients with Bone Metastases Treated with Zoledronic Acid
  Thursday, 26 April 2007
• Advanced Prostate Cancer - Comparative Reviews of the Major Guidelines
  Thursday, 12 April 2007
• BJU Intl - Bone and Prostate Cancer Cell Interactions in Metastatic Prostate Cancer
  April 2007
• EAU 2007 - Session on Management Options in Metastatic Prostate Cancer and Bone Health
  Friday, 30 March 2007
• EAU 2007 - Step-Up to CAB May Prolong PSA Response in Patients with Metastatic or Locally Advanced Prostate Cancer
  Thursday, 29 March 2007
• EAU 2007 - Hormonal Treatment for Localized and Advanced Prostate Cancer
  Thursday, 29 March 2007
• EAU 2007 - EAU Session on Management Options in Metastatic Prostate Cancer 1
  Wednesday, 21 March 2007
• The Natural History of Noncastrate Metastatic Prostate Cancer after Radical Prostatectomy
  Wednesday, 03 January 2007
• Absolute Prostate-Specific Antigen Value After Androgen Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162)
  Tuesday, 12 December 2006
• Survey Reveals Physician Misconceptions of Combined Hormonal Therapy for Advanced Prostate Cancer
  Wednesday, 01 November 2006
• When a Patient is Diagnosed with Prostate Cancer, what Determines Whether he will Receive Early Androgen Ablation? Study Shows that his Choice of Urologist may be More Important Than Tumor Characteristics
  Wednesday, 16 August 2006
• Increased Serum Levels Of Bone-specific Alkaline Phosphatase Correlate With Shorter Survival In Men With Hormone Refractory Prostate Cancer
  Wednesday, 05 July 2006
• AUA 2006 - Society of Urologic Oncology Meeting: Hot Topics in GU Cancer Biology And Translation; Bone and the Microenvironment
  May 2006
• AUA 2006 - Society of Urologic Oncology Meeting: Hot Topics in GU Cancer Biology And Translation; Bone and the Microenvironment
  May 2006
• AUA 2006 - ABST [130] Role Calcium Intake on Bone Mineral Density in Prostate Cancer Patients Under Androgen Deprivation Therapy
  May 2006
• AUA 2006 - ABST [410] Bone Mineral Density in Prostate Cancer Patients Undergoing Initial Androgen Deprivation Therapy: Zoledronic Acid vs. Placebo
  May 2006
• AUA 2006 - ABST [1197] Prognostic value of hemoglobin change after initiation of androgen deprivations therapy for newly diagnosed metastatic prostate cancer: a multivariate analysis of SWOG 8894
  May 2006
• ASCO 2006 Prostate Cancer Symposium - A Presentation on the Use of Zoledronic Acid (ZA) Initiated During the First Year of Androgen Deprivation Therapy (ADT) Increases Bone Mineral Density (BMD) and Suppresses Bone Turnover Markers in Prostate Cancer Patients
  June 2006
• ASCO 2006 Prostate Cancer Symposium - An Abstract Presentation on the Efficacy and Safety of Zoledronic Acid in the Treatment of Skeletal Metastases in Patients with Hormone Refractory Prostate Cancer: A Prospective, Multicenter, Open Label Trial
  June 2006
• EAU 2006 - ABST [139] Zoledronic acid as adjunct to androgen deprivation therapy reduces bone loss in men with prostate cancer
  April 2006
• EAU 2006 - ABST [141] Zoledronic acid reduces skeletal morbidity regardless of previous skeletal events in men with prostate cancer and bone metastases
  April 2006
• EAU 2006 - ABST [142] Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer
  April 2006
• EAU 2006 - ABST [288] A phase II clinical study of high-dose Calcitriol plus Docetaxel and Zoledronic acid in hormone-refractory prostate cancer (HRPC)
  April 2006
• Combination Of Zoledronic Acid And Docetaxel Inhibits Prostate Cancer Growth In Experimental Bone Study
  Friday, 14 April 2006
• An Argument For The Use Of Zoledronic Acid In Androgen-Sensitive Prostate Cancer
  Monday, 20 March 2006
• Androgen Deprivation Leads To Bone Loss In Men With Prostate Cancer
  Thursday, 22 December 2005
• Disease Extent In Bone And Bone Pain Predict Skeletal-Related Complications In Patients With Metastatic Prostate Cancer
  Tuesday, 08 November 2005
• BJU Intl - Zoledronic Acid Is Effective In Preventing And Delaying Skeletal Events In Patients With Bone Metastases Secondary To Genitourinary Cancers (PDF)
  November 2005
• Randomized, Open Label, Prospective Study Suggests Zoledronic Acid May Prevent the Development of Bone Metastases in Patients with Advanced Cancer
  Monday, 08 August 2005
• ASCO 2005 - #364: Efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with hormone refractory prostate cancer: A prospective, multicenter, open-label trial
  May 2005
• ASCO 2005 - #192: Zoledronic acid (ZA) initiated during the first year of androgen deprivation therapy (ADT) increases bone mineral density (BMD) and suppresses bone turnover markers in prostate cancer patients
  May 2005
• Novartis Drug Aids Bones In Paget's Disease-Study
  Thursday, 01 September 2005
• EAU 2005 - ABST[89] PHARMACOGENOMICS OF ZOLEDRONIC ACID: INHIBITORY EFFECTS ON TUMOUR CELL GENE EXPRESSION PROFILES
  March 2005
• EAU 2005 - ABST[567] ZOLEDRONIC ACID PROVIDES LONG-TERM REDUCTION OF BONE PAIN IN PATIENTS WITH BONE METASTASES SECONDARY TO PROSTATE CANCER
  March 2005
• EAU 2005 - ABST[573] METABOLOMICS THERAPY WITH 2-OXO-GLUTARIC ACID SOLUTION (KARAL SOLUTION) IN PATIENTS WITH HORMONE AND CHEMOTHERAPY INSENSITIVE METASTATIC PROSTATE CANCER LEADS TO AN INCREASE OF PSA DOUBLING TIME AND DECREASE OF BLOOD SUPPLY IN TUMOUR LESIONS
  March 2005
• EAU 2005 - ABST[898] Combined Androgen Blockade Six Months a Year in the Management of Advanced Prostate Cancer: A Randomized Study
  March 2005
• EAU 2005 - ABST[993] WEEKLY DOCETAXEL, ZOLEDRONIC ACID, AND ESTRAMUSTINE IN METASTATIC ANDROGEN-INDEPENDENT PROSTATE CANCER (MAIP)
  March 2005
• EAU 2005 - ABST[982] KETOKONAZOL/HYDROCORTISONE VERSUS ESTRAMUSTINPHOSPHATE IN THE MANAGEMENT OF PSA PROGRESSION FOLLOWING PRIMARY ANDROGEN DEPRIVATION FOR METASTATIC PROSTATE CANCER
  March 2005
• Bone Turnover Marker Levels Predict Outcome of Solid Tumor Metastases to Bone
  Wednesday, 19 January 2005
• Pamidronate Disodium Does Not Decrease Pain Morbidity Compared to Placebo in a Randomized Trial of Men with Metastatic Prostate Cancer
  Monday, 09 February 2004
• Single-fraction Radiotherapy Effectively Treats Painful Bone Metastases
  Monday, 20 October 2003
• Maximal Androgen Blockade for the Treatment of Metastatic Prostate Cancer
  5 February 2003
• Zoledronic Acid Reduces Risk of Skeletal Events with Metastatic Prostate Cancer
  Wednesday, 02 October 2002

Please log-in or register in order to submit comments.

Powered by AkoComment!